Cite
HARVARD Citation
Pant, S. et al. (n.d.). 376 A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors. Journal for immunotherapy of cancer. p. A229. [Online].